Cellectis (NASDAQ:CLLS) – Analysts at Jefferies Group issued their Q4 2018 EPS estimates for shares of Cellectis in a research report issued to clients and investors on Tuesday, March 13th, according to Zacks Investment Research. Jefferies Group analyst B. Amin forecasts that the biotechnology company will post earnings of ($0.67) per share for the quarter. Jefferies Group also issued estimates for Cellectis’ FY2021 earnings at $1.52 EPS and FY2022 earnings at $2.44 EPS.
CLLS has been the topic of a number of other reports. Oppenheimer reissued an “outperform” rating and issued a $40.00 price objective on shares of Cellectis in a research note on Thursday, December 28th. BidaskClub downgraded Cellectis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 16th. Nomura raised their price objective on Cellectis to $73.00 and gave the company a “buy” rating in a research note on Wednesday, March 14th. Guggenheim started coverage on Cellectis in a research note on Friday, March 16th. They issued a “neutral” rating on the stock. Finally, Zacks Investment Research downgraded Cellectis from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $42.67.
Shares of CLLS stock traded down $0.17 during trading on Thursday, reaching $28.83. The company had a trading volume of 777,592 shares, compared to its average volume of 578,716. Cellectis has a one year low of $21.25 and a one year high of $38.85. The company has a market capitalization of $1,035.80, a price-to-earnings ratio of -10.37 and a beta of 1.86.
Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.12). Cellectis had a negative net margin of 298.01% and a negative return on equity of 35.63%. The company had revenue of $6.91 million during the quarter, compared to the consensus estimate of $10.10 million.
A number of hedge funds and other institutional investors have recently modified their holdings of CLLS. Perceptive Advisors LLC bought a new position in Cellectis in the 4th quarter worth approximately $10,203,000. BlackRock Inc. bought a new position in Cellectis in the 4th quarter worth approximately $4,422,000. Sphera Funds Management LTD. increased its position in Cellectis by 71.1% in the 3rd quarter. Sphera Funds Management LTD. now owns 348,736 shares of the biotechnology company’s stock worth $9,922,000 after buying an additional 144,972 shares during the period. Bain Capital Public Equity Management LLC bought a new position in Cellectis in the 4th quarter worth approximately $2,848,000. Finally, Millennium Management LLC increased its position in Cellectis by 1,356.2% in the 4th quarter. Millennium Management LLC now owns 104,290 shares of the biotechnology company’s stock worth $3,040,000 after buying an additional 97,128 shares during the period. 20.31% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Cellectis (CLLS) to Post Q4 2018 Earnings of ($0.67) Per Share, Jefferies Group Forecasts” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/08/jefferies-group-weighs-in-on-cellectis-sas-q4-2018-earnings-clls.html.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Get a free copy of the Zacks research report on Cellectis (CLLS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.